309 related articles for article (PubMed ID: 32994552)
1. Assessment of plasma lyso-Gb
Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
[TBL] [Abstract][Full Text] [Related]
4. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
5. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
6. Migalastat: A Review in Fabry Disease.
McCafferty EH; Scott LJ
Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
[TBL] [Abstract][Full Text] [Related]
8. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy.
Auray-Blais C; Lavoie P; Martineau T; Ntumba GK; Gamrani M; Khan A; Altarescu G; Lehman A; Goker-Alpan O; Nowak A; West ML; Bichet DG
Bioanalysis; 2023 Dec; 15(23):1421-1437. PubMed ID: 37847061
[No Abstract] [Full Text] [Related]
10. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
Schiffmann R; Bichet DG; Jovanovic A; Hughes DA; Giugliani R; Feldt-Rasmussen U; Shankar SP; Barisoni L; Colvin RB; Jennette JC; Holdbrook F; Mulberg A; Castelli JP; Skuban N; Barth JA; Nicholls K
Orphanet J Rare Dis; 2018 Apr; 13(1):68. PubMed ID: 29703262
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
[TBL] [Abstract][Full Text] [Related]
12. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
[TBL] [Abstract][Full Text] [Related]
13. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
Hughes DA; Bichet DG; Giugliani R; Hopkin RJ; Krusinska E; Nicholls K; Olivotto I; Feldt-Rasmussen U; Sakai N; Skuban N; Sunder-Plassmann G; Torra R; Wilcox WR
J Med Genet; 2023 Jul; 60(7):722-731. PubMed ID: 36543533
[TBL] [Abstract][Full Text] [Related]
14. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
15. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
16. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
17. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
19. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
20. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
